Search for an ETF or holding
Larimar Therapeutics, Inc. (LRMR) is an American company in the healthcare sector, listed on NASDAQ. Market capitalization of 332 million USD (small-cap).
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.